Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis

Current Opinion in Investigational Drugs

Volumn 11, Issue 9, 2010, Pages 989-996

  Smith, Jonathan D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apolipoprotein A I; HDL; mimetic peptide; reverse cholesterol transport

Indexed keywords

5A LIPID COMPLEX; 5F PEPTIDE; APOLIPOPROTEIN A1; APP 018; ATI 521; ATI 5261; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; ETC 216; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPEPTIDE; NICLOSAMIDE; NICOTINIC ACID; PLACEBO; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN; RVX 208; TORCETRAPIB; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; HEART DEATH; HEART DISEASE; HUMAN; MOLECULAR MECHANICS; NONHUMAN; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LIPOPROTEINS, HDL; PEPTIDES; RISK REDUCTION BEHAVIOR;

EID: 77956244457     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De SG, Ferguson TB, Ford E, Furie K, Gillespie C, Go A et al: Executive summary: Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation (2010) 121(7):948-954.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation (1998) 97(18):1837-1847.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 79(1):8-15.
4. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA (1994) 91(20):9607-9611.
5. Paszty C, Maeda N, Verstuyft J, Rubin EM: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest (1994) 94(2):899-903.
6. The Coronary Drug Project Research Group:Clofibrate and niacin in coronary heart disease. JAMA (1975) 231(4):360-381.
7. Brown BG, Zhao XQ: Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol (2008) 101(8A):58B-62B.
8. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S et al: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA (2003) 290(17):2292-2300.
9. Bielicki JK, McCall MR, Stoltzfus LJ, Ravandi A, Kuksis A, Rubin EM, Forte TM: Evidence that apolipoprotein A-IMilano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol. Arterioscler Thromb Vasc Biol (1997) 17(9):1637-1643.
10. avari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L: A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-IMilano dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J Biol Chem (2007) 282(8):5125-5132.
11. Weibel GL, Alexander ET, Joshi MR, Rader DJ, Lund-Katz S, Phillips MC, Rothblat GH: Wild-type apoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol (2007) 27(9):2022-2029.
12. Glomset JA: The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res (1968) 9(2):155-167.
13. Yvan-Charvet L, Wang N, Tall AR: Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol (2010) 30(2):139-143.
14. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ: Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 108(6):661-663.
15. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest (1991) 88(6):2039-2046.
16. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol (1995) 15(11):1987-1994.
17. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, Rye KA, Barter PJ, Vadas MA, Xia P: High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation (2004) 109(17):2116-2122.
18. Mineo C, Yuhanna IS, Quon MJ, Shaul PW: High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem (2003) 278(11):9142-9149.
19. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, Rader DJ et al: High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res (2006) 98(1):63-72.
20. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM: The role of dysfunctional HDL in atherosclerosis. J Lipid Res (2009) 50(Suppl):S145-S149.
21. Smith JD: Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol (2010) 30(2):151-155.
22. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation (2003) 108(22):2751-2756.
23. McGillicuddy FC, de la Llera MM, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP: Inflammation impairs reverse cholesterol transport in vivo. Circulation (2009) 119(8):1135-1145.
24. Annema W, Nijstad N, Tolle M, de Boer JF, Buijs RV, Heeringa P, van der Giet M, Tietge UJ: Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase AJ Lipid Res (2010) 51(4):743-754.
25. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H et al: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 114(4):529-541.
26. Natarajan P, Ray KK, Cannon CP: High-density lipoprotein and coronary heart disease: Current and future therapies. J Am Coll Cardiol (2010) 55(13):1283-1299.
27. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL et al: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 357(21):2109-2122.
28. Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L et al: RVX-208: A small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol (2010) 55(23):2580-2589.
29. McNeill E: RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr Opin Investig Drugs (2010) 11(3):357-364.
30. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, Rothblat G, de la Llera-Moya M, Asztalos B, Perlman T, Zheng C et al: Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res (2009) 50(5):894-907.
31. Lipid Sciences Inc: Lipid Sciences: Form 8K. Press Release (2008): October 03.
32. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V: High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest (1989) 60(3):455-461.
33. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest (1990) 85(4):1234-1241.
34. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol (2005) 25(11):2416-2421.
35. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Natio M et al: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol (1995) 15(11):1882-1888.
36. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E: Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: The Limone sul Garda study. Circulation (2001) 103(15):1949-1954.
37. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B: Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation (1998) 97(8):780-785.
38. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B: High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization. Circulation (2001) 103(25):3047-3050.
39. Kaul S, Coin B, Hedayiti A, Yano J, Cercek B, Chyu KY, Shah PK: Rapid reversal of endothelial dysfunction in hyper cholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-Iphospholipid complex. J Am Coll Cardiol (2004) 44(6):1311-1319.
40. Parolini C, Marchesi M, Lorenzon P, Castano M, Balconi E, Miragoli L, Chaabane L, Morisetti A, Lorusso V, Martin BJ, Bisgaier CL et al: Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl- 2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: In vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol (2008) 51(11):1098-1103.
41. Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V et al: Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: Magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol (2008) 51(11):1104-1109.
42. The Medicines Company: The Medicines Company acquires apoA-I Milano from Pfizer. Press Release (2009): December 22.
43. Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ: Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by apoA-IJ Cell Mol Med (2009) 13(9B):3226-3235.
44. Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M, Rothblat GH, Phillips MC, Rader DJ: Macrophage reverse cholesterol transport in mice expressing apoA-I Milano. Arterioscler Thromb Vasc Biol (2009) 29(10):1496-1501.
45. Cho KH, Kim JR: A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation. Exp Mol Med (2009) 41(6):417-428.
46. Alexander ET, Tanaka M, Kono M, Saito H, Rader DJ, Phillips MC: Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J Lipid Res (2009) 50(7):1409-1419.
47. Parolini C, Chiesa G, Gong E, Caligari S, Cortese MM, Koga T, Forte TM, Rubin EM: Apolipoprotein A-I and the molecular variant apoA-IEvaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis (2005) 183(2):222-229.
48. Parolini C, Chiesa G, Zhu Y, Forte T, Caligari S, Gianazza E, Sacco MG, Sirtori CR, Rubin EM: Targeted replacement of mouse apolipoprotein A-I with human apoA-I or the mutant apoA-IEvidence of apoA-IM impaired hepatic secretion. J Biol Chem (2003) 278(7):4740-4746.
49. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ: Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol (2007) 6:15.
50. Feng Y, Van Craeyveld E, Jacobs F, Lievens J, Snoeys J, De Geest B: Wild-type apo A-I and apo A-IMilano gene transfer reduce native and transplant arteriosclerosis to a similar extent. J Mol Med (2009) 87(3):287-297.
51. Wang L, Sharifi BG, Pan T, Song L, Yukht A, Shah PK: Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol (2006) 48(7):1459-1468.
52. Carlson LA: Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr Metab Cardiovasc Dis (1995) 5:85-91.
53. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr: Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res (1993) 34(12):2207-2215.
54. Nanjee MN, Doran JE, Lerch PG, Miller NE: Acute effects of intravenous infusion of apoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol (1999) 19(4):979-989.
55. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, Miller NE: Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol (1996) 16(9):1203-1214.
56. Cuchel M, Lund-Katz S, Llera-Moya M, Millar JS, Chang D, Fuki I, Rothblat GH, Phillips MC, Rader DJ: Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages. Arterioscler Thromb Vasc Biol (2010) 30(3):526-532.
57. Hovorka R, Nanjee MN, Cooke CJ, Miller IP, Olszewski WL, Miller NE: Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans. J Lipid Res (2006) 47(5):975-981.
58. Kujiraoka T, Hattori H, Ito M, Nanjee MN, Ishihara M, Nagano M, Iwasaki T, Cooke CJ, Olszewski WL, Stepanova IP, Egashira T et al: Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid. Atherosclerosis (2004) 176(1):57-62.
59. Kujiraoka T, Nanjee MN, Oka T, Ito M, Nagano M, Cooke CJ, Takahashi S, Olszewski WL, Wong JS, Stepanova IP, Hamilton RL et al: Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol (2003) 23(9):1653-1659.
60. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE: Intravenous apoA-I/lecithin discs increase pre-â-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res (2001) 42(10):1586-1593.
61. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY et al: High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation (2009) 119(15):2103-2111.
62. Spieker LE, Sudano I, Hürlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Lüscher TF, Noll G: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 105(12):1399-1402.
63. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES: Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 107(23):2944-2948.
64. Nieuwdorp M, Vergeer M, Bisoendial RJ, op 't Roodt J, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, Kastelein JJ, Stroes ES: Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia (2008) 51(6):1081-1084.
65. Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, Arnet B, van den Ende A, ten Cate JW, van Deventer SJ: Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost (1997) 77(2):303-307.
66. van Leuven SI, Birjmohun RS, Franssen R, Bisoendial RJ, de Kort H, Levels JH, Basser RL, Meijers JC, Kuivenhoven JA, Kastelein JJ, Stroes ES: ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans. J Thromb Haemost (2009) 7(2):347-354.
67. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 184(5):1601-1608.
68. Lerch PG, Spycher MO, Doran JE: Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost (1998) 80(2):316-320.
69. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP: Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 120(21):2095-2104.
70. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, Celermajer DS et al: Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol (2009) 53(11):962-971.
71. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC et al: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA (2007) 297(15):1675-1682.
72. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, Dart AM: Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res (2008) 103(10):1084-1091.
73. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM: The amphipathic helix in the exchangeable apolipoproteins: A review of secondary structure and function. J Lipid Res (1992) 33(2):141-166.
74. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, Segrest JP: Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 260(18):10248-10255.
75. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC et al: Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 42(7):1096-1104.
76. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM: Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 49(11):2302-2311.
77. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S et al: Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res (2003) 44(4):828-836.
78. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, Fogelman AM, Segrest JP, Anantharamaiah GM: A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 42(4):545-552.
79. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM: Oral administration of an apo A-I mimetic peptide synthesized from amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 105(3):290-292.
80. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM: Oral 4F causes formation of pre-â high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 109(25):3215-3220.
81. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM: 4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 25(7): 1426-1432.
82. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK: Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation (2004) 110(12):1701-1705.
83. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ: Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide 4F in high-risk cardiovascular patients. J Lipid Res (2008) 49(6):1344-1352.
84. Novartis AG: Novartis shows dynamic momentum in industry-leading pipeline. Press Release (2005): January 20.
85. Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, Remaley AT: Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem (2008) 283(47):32273-32282.
86. Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Sviridov D, Remaley AT: 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther (2010) 334(2):634-641.
87. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S: A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res (2010) 51(6):1496-1503.
88. Navab M, Ruchala P, Waring AJ, Lehrer RI, Hama S, Hough G, Palgunachari MN, Anantharamaiah GM, Fogelman AM: A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all l-amino acids. J Lipid Res (2009) 50(8): 1538-1547.